Vanda Pharma Files 8-K on Operations & Financial Condition

TL;DR

**Vanda Pharma just dropped an 8-K on its financials, time to check their numbers.**

AI Summary

Vanda Pharmaceuticals Inc. filed an 8-K on February 7, 2024, to report on its results of operations and financial condition. This filing indicates that the company is providing an update on its financial performance, which is crucial for investors to understand the company's current health and future prospects. For shareholders, this matters because it offers transparency into how the company is managing its finances and operating its business, directly impacting their investment's value.

Why It Matters

This filing provides an update on Vanda Pharmaceuticals' financial health, which is essential for investors to assess the company's performance and make informed decisions about their holdings.

Risk Assessment

Risk Level: low — This 8-K is a routine disclosure of financial condition and operations, not indicating any immediate new risks or major changes.

Analyst Insight

A smart investor would review the detailed financial statements and results of operations that will be included as exhibits to this 8-K to understand the company's current performance and future outlook before making any investment decisions.

Key Players & Entities

• Vanda Pharmaceuticals Inc. (company) — the registrant filing the 8-K
• February 7, 2024 (date) — date of earliest event reported and filing date
• 001-34186 (other) — Commission File No.
• The Nasdaq Global Market (other) — exchange where Vanda's Common Stock is registered
• $0.001 (dollar_amount) — par value per share of Common Stock

FAQ

Key Financial Figures

• $0.001 — ich registered Common Stock, par value $0.001 per share VNDA The Nasdaq Global Market

Filing Documents

• vnda-20240207.htm (8-K) — 35KB
• vnda8-k272024exhibit991.htm (EX-99.1) — 131KB
• vandaq32019earningsca_imag.jpg (GRAPHIC) — 48KB
• 0001628280-24-003693.txt ( ) — 376KB
• vnda-20240207.xsd (EX-101.SCH) — 2KB
• vnda-20240207_lab.xml (EX-101.LAB) — 24KB
• vnda-20240207_pre.xml (EX-101.PRE) — 13KB
• vnda-20240207_htm.xml (XML) — 3KB

02. Results of Operations and Financial Condition

Item 2.02. Results of Operations and Financial Condition. On February 7, 2024, Vanda Pharmaceuticals Inc. ("Vanda") issued a press release and is holding a conference call regarding its results of operations and financial condition for the quarter and full year ended December 31, 2023. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. Various statements to be made during the conference call are "forward-looking statements" under the securities laws, including, but not limited to, statements regarding Vanda's commercial products, plans and opportunities, as well as statements about Vanda's products in development and the related clinical development and regulatory timelines and commercial potential for such products. Words such as, but not limited to, "believe," "expect," "anticipate," "estimate," "intend," "plan," "project," "target," "goal," "likely," "will," "would," and "could," or the negative of these terms and similar expressions or words, identify forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Forward-looking statements are based upon current expectations and assumptions that involve risks, changes in circumstances and uncertainties. Important factors that could cause actual results to differ materially from those reflected in Vanda's forward-looking statements include, among others, Vanda's assumptions regarding the strength of its business in the U.S. and Vanda's ability to complete the clinical development of, and obtain regulatory approval for, the products in its pipeline. Therefore, no assurance can be given that the actual results or developments anticipated by Vanda will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Vanda. Forward-looking statements made during the call should be evaluated toge

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release of Vanda Pharmaceuticals Inc. dated February 7, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: February 7, 2024 VANDA PHARMACEUTICALS INC. By: /s/ Timothy Williams Name: Timothy Williams Title: Senior Vice President, General Counsel and Secretary

View Full Filing

View this 8-K filing on SEC EDGAR